KBC Group NV Has $64,000 Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

KBC Group NV cut its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 25.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 5,180 shares of the company’s stock after selling 1,774 shares during the quarter. KBC Group NV’s holdings in Syndax Pharmaceuticals were worth $64,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SNDX. Tang Capital Management LLC acquired a new position in Syndax Pharmaceuticals during the 4th quarter worth approximately $1,322,000. Polar Asset Management Partners Inc. acquired a new position in Syndax Pharmaceuticals during the 4th quarter worth approximately $1,124,000. Jump Financial LLC boosted its position in Syndax Pharmaceuticals by 80.8% during the 4th quarter. Jump Financial LLC now owns 173,890 shares of the company’s stock worth $2,299,000 after acquiring an additional 77,699 shares during the last quarter. Simplify Asset Management Inc. boosted its position in Syndax Pharmaceuticals by 20.8% during the 4th quarter. Simplify Asset Management Inc. now owns 147,641 shares of the company’s stock worth $1,952,000 after acquiring an additional 25,456 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Syndax Pharmaceuticals by 7.5% during the 4th quarter. Northern Trust Corp now owns 792,750 shares of the company’s stock worth $10,480,000 after acquiring an additional 55,144 shares during the last quarter.

Syndax Pharmaceuticals Stock Up 0.2%

SNDX opened at $8.75 on Wednesday. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $25.07. The stock’s fifty day simple moving average is $10.31 and its 200 day simple moving average is $12.37. The company has a current ratio of 5.80, a quick ratio of 5.75 and a debt-to-equity ratio of 1.53. The stock has a market cap of $752.94 million, a PE ratio of -2.27 and a beta of 0.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.06. Syndax Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 757.53%. The business had revenue of $20.04 million for the quarter, compared to analysts’ expectations of $15.88 million. During the same quarter in the prior year, the business earned ($0.85) EPS. The firm’s revenue for the quarter was up 1900.0% on a year-over-year basis. As a group, research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

SNDX has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, March 20th. Wall Street Zen raised Syndax Pharmaceuticals to a “sell” rating in a research report on Tuesday, May 6th. Scotiabank upped their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a “sector perform” rating in a research report on Tuesday, May 6th. Finally, Guggenheim reiterated a “buy” rating and set a $32.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.80.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).